Sanofi has received approval from the US Food and Drug Administration for Priftin (rifapentine) in combination with isoniazid for a new indication for the treatment of latent tuberculosis infection in patients two years of age and older at high risk of progression to tuberculosis disease. Approved in the United States since 1998, Priftin is an antimycobacterial used in combination with one or more antituberculosis drugs for the treatment of active pulmonary TB caused by Mycobacterium tuberculosis.

Currently, Priftin is only available in the United States, and Sanofi is exploring the potential for regulatory approvals in other countries. Priftin is manufactured by Sanofi in Brindisi and Anagni, Italy.

Source: Sanofi